Clinical trial
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in…
NCT00416520 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00416520 |
|---|---|
| Title | A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia |
| Official title | A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease, Hyperphosphatemia |
| Intervention type | Drug |
| Interventions | MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Placebo, Another phosphate binder (Sevelamer) |
| Enrollment | 336 |
| Start date | Jun 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Dec 28, 2006 |
| Last update posted | Jan 8, 2026 |
| Countries | Australia, Austria, Czechia, France, Germany, Hungary, Italy, Poland, South Africa, Spain, United Kingdom |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: